The Institute of Cancer Research/Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK.
Nat Rev Cancer. 2013 Apr;13(4):273-82. doi: 10.1038/nrc3432. Epub 2013 Feb 21.
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.
恶性腹水对卵巢癌的治疗提出了重大的临床挑战，但也为转化研究提供了丰富的机会。腹水及其细胞成分的可及性使其成为研究预后和预测生物标志物、药效动力学标志物以及分子谱分析的肿瘤组织的绝佳来源。在这篇观点文章中，我们讨论了对其病理生理学的理解的最新进展、用于描述其分子特征的新方法的发展，以及如何利用这些发现来改善恶性腹水的治疗，特别是在卵巢癌的背景下。
